The Robert Larner College of Medicine at the University of Vermont, Burlington, VT 05401, USA.
Department of Obstetrics, Gynecology and Reproductive Sciences at the Robert Larner College of Medicine at the University of Vermont, Burlington, VT 05401, USA.
J Subst Abuse Treat. 2019 Mar;98:73-77. doi: 10.1016/j.jsat.2018.12.001. Epub 2018 Dec 6.
Women with opioid use disorder have higher rates of unplanned pregnancies, shorter interpregnancy intervals and lower rates of contraceptive use compared to women without substance use disorders. This contributes to worse perinatal and reproductive health outcomes for this population. It has been suggested that co-location of medication assisted treatment (MAT) and reproductive health services could allow for improved outcomes among women with substance use disorders. The aim of this study was to determine if location where women received MAT influenced their pregnancy planning, interpregnancy interval or uptake of postpartum contraception between subsequent pregnancies.
We conducted a retrospective chart review at the University of Vermont Medical Center (UVMMC). Women were eligible for the study if they had two consecutive deliveries at UVMMC between 2009 and 2015 and if they received MAT during one or both pregnancies. Women in this community can receive MAT through a public MAT opioid treatment program (methadone or buprenorphine), a community MAT program (buprenorphine), or through an obstetric provider with co-location of prenatal care and MAT (buprenorphine). Demographics and maternal and neonatal outcomes were collected and descriptive statistics were performed.
A total of 98 women were included in the study. Of the women with documented pregnancy intention status, 84% were unplanned, for both pregnancies. Over half of women had a short interpregnancy interval (56.1%), defined as <18 months between consecutive pregnancies. Half of women (50%) did not receive any contraceptive method in the postpartum period. Furthermore, many patients (42.2%) desired long acting reversible contraception (LARC), but only 9.3% received it. Outcomes were not statistically different among the models of care.
Colocation of MAT with antenatal care did not improve pregnancy planning, interpregnancy interval, or uptake of postpartum contraception. Decisions regarding family planning and continued engagement with the health care system following pregnancy remain challenges in this group of women.
与没有物质使用障碍的女性相比,患有阿片类药物使用障碍的女性意外怀孕的比例更高,两次妊娠之间的间隔时间更短,使用避孕措施的比例更低。这导致该人群的围产期和生殖健康结果更差。有人建议,将药物辅助治疗 (MAT) 和生殖健康服务集中在一起,可以改善物质使用障碍女性的治疗效果。本研究旨在确定女性接受 MAT 的地点是否会影响她们在下一次妊娠中的妊娠计划、两次妊娠之间的间隔时间或产后避孕措施的使用。
我们在佛蒙特大学医学中心 (UVMMC) 进行了回顾性病历审查。如果女性在 2009 年至 2015 年期间在 UVMMC 连续分娩两次,并且在一次或两次妊娠期间接受 MAT,则有资格参加本研究。在这个社区,女性可以通过公共 MAT 阿片类药物治疗项目(美沙酮或丁丙诺啡)、社区 MAT 项目(丁丙诺啡)或通过产前护理和 MAT 联合的产科提供者获得 MAT。收集了人口统计学、母婴和新生儿结局数据,并进行了描述性统计。
共有 98 名女性纳入研究。在有记录的妊娠意向状态的女性中,84%的女性两次妊娠均为意外妊娠。超过一半的女性两次妊娠之间的间隔时间较短(56.1%),定义为连续妊娠之间<18 个月。一半的女性(50%)在产后期间没有使用任何避孕方法。此外,许多患者(42.2%)希望使用长效可逆避孕措施(LARC),但只有 9.3%的人使用了该方法。不同的治疗模式之间的结果没有统计学差异。
MAT 与产前保健的集中化并没有改善妊娠计划、两次妊娠之间的间隔时间或产后避孕措施的使用。在这组女性中,关于计划生育和产后继续参与医疗保健系统的决策仍然是挑战。